97-26732. Authorization of DEA Laboratory Directors to Release DEA Laboratory Information to Federal and State Prosecutors; Redelegation of Authority  

  • [Federal Register Volume 62, Number 195 (Wednesday, October 8, 1997)]
    [Rules and Regulations]
    [Page 52493]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-26732]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF JUSTICE
    
    28 CFR Part 0
    
    
    Authorization of DEA Laboratory Directors to Release DEA 
    Laboratory Information to Federal and State Prosecutors; Redelegation 
    of Authority
    
    AGENCY: Department of Justice.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: This final rule authorizes Drug Enforcement Administration 
    (DEA) Laboratory Directors to release DEA laboratory information, and 
    to authorize testimony by DEA laboratory personnel, in response to 
    Federal and State prosecutors' requests for same.
    
    EFFECTIVE DATE: January 22, 1997.
    
    FOR FURTHER INFORMATION CONTACT:
    Jayme S. Walker, Associate Chief Counsel, Office of Chief Counsel, Drug 
    Enforcement Administration, (202) 307-8030.
    
    SUPPLEMENTARY INFORMATION: The Administrator of the DEA is authorized 
    at 28 CFR 0.103(a) to release DEA information, and to authorize DEA 
    personnel to testify, in response to requests from Federal and State 
    prosecutors who are engaged in the enforcement of laws which are 
    related to controlled substances. The Administration is authorized by 
    Sec. 0.104 to redelegate to any of his subordinates any of the powers 
    and functions assigned to him by subpart R.
        DEA Special Agents in Charge were previously delegated the 
    authority to grant Sec. 0.103(a) requests as they related to DEA 
    Special Agents, Diversion Investigators, and other personnel under this 
    supervision, at 28 CFR, Appendix to Subpart R, section 2. This 
    redelegation will amend section 2 to give DEA Laboratory Directors 
    corresponding authority over DEA laboratory information and testimony, 
    specifically, the authority to release DEA laboratory information, and 
    to authorize the testimony of DEA laboratory personnel, under the 
    circumstances described at 28 CFR 0.103(a).
        The Administrator certifies that this action will have no impact 
    upon entities whose interests must be considered under the Regulatory 
    Flexibility Act (5 U.S.C. 601). Pursuant to sections 1 (a)(3) and 1(b) 
    of Executive Order 12291, this rule is not a major rule and relates 
    only to the organization of functions with DEA. Accordingly, it has not 
    been reviewed by the Office of Management and Budget. This action has 
    been analyzed in accordance with Executive Order 12612 and it has been 
    determined that this matter has no federalism implications which would 
    warrant the preparation of a Federalism Assessment.
    
    List of Subjects in 28 CFR Part 0
    
        Authority Delegations (Government Agencies), Organizations and 
    functions (Government Agencies).
        For the reasons set forth above, and pursuant to the authority 
    vested in the Administrator of the Drug Enforcement Administration by 
    28 CFR 0.100 and 0.104, and 21 U.S.C. 871, title 28 of the Code of 
    Federal Regulations, part 0, Appendix to Subpart R, Redelegation of 
    Functions, section 2, is amended as follows:
    
    PART 0--ORGANIZATION OF THE DEPARTMENT OF JUSTICE
    
        1. The authority citation for part 0 continues to read as follows:
    
        Authority: 5 U.S.C. 301; 28 U.S.C. 509, 510, 515-519.
    
        2. The Appendix to subpart R, section 2, is revised to read as 
    follows:
    
    Appendix to Subpart R--Redelegation of Functions
    
    * * * * *
        Sec. 2. Supervisors. All Special Agents-in-Charge of the DEA, and 
    the FBI are authorized to conduct enforcement hearings under 21 U.S.C. 
    883, and to take custody of seized property under 21 U.S.C. 881. All 
    Special Agents-in-Charge of the DEA and the FBI are authorized to 
    release information pursuant to 28 CFR 0.103(a) (1) and (2) which is 
    obtained by the DEA and the FBI, and to authorize the testimony of DEA 
    and FBI officials in response to prosecution subpoenas under 28 CFR 
    0.103(a)(3). All DEA Laboratory Directors are authorized to release 
    information pursuant to 28 CFR 0.103(a) (1) and (2) which is obtained 
    by a DEA laboratory, and to authorize the testimony of DEA laboratory 
    personnel in response to prosecution subpoenas under 28 CFR 
    0.103(a)(3). All DEA Special Agents-in-Charge are authorized to take 
    custody of, and make disposition of, controlled substances seized 
    pursuant to 21 U.S.C. 824(g).
    * * * * *
        Dated: September 25, 1997.
    Thomas A. Constantine,
    Administrator.
    [FR Doc. 97-26732 Filed 10-7-97; 8:45 am]
    BILLING CODE 4410-09-M
    
    
    

Document Information

Published:
10/08/1997
Department:
Justice Department
Entry Type:
Rule
Action:
Final rule.
Document Number:
97-26732
Dates:
January 22, 1997.
Pages:
52493-52493 (1 pages)
PDF File:
97-26732.pdf
CFR: (2)
28 CFR 2
28 CFR 0.104